The prospects for this trio are better than in the current year, which has been rough on all three.
Let's check the charts of this generic drug maker.
Let's check out the charts to see if the rally can still push higher.
Here's what to expect in the weeks and months ahead.
The biotechnology company is seeing heavier trading volume in its stock on days when its shares trade higher.
Here's where resistance may develop.
This is somewhat of a speculative name.
One is a footwear company and the other a drugmaker that was this writer's "top pick" for the balance of the year last spring.
Plus, the Treasury yield spread moved in the wrong direction Tuesday, signaling possible economic hardship ahead.
The stock reached its price target, so now what do the charts say?